Sodium-Glucose Cotransporter 2 Inhibitor Protection Against Adverse Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes.

New treatments for type 2 diabetes are required to demonstrate cardiovascular safety in dedicated cardiovascular outcomes trials (CVOTs). This article reviews available evidence on cardiovascular, renal, and safety outcomes from CVOTs and real-world analyses of sodium-glucose cotransporter 2 inhibitors, along with considerations for their use in clinical practice.

Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Medications for Type 2 Diabetes Mellitus: A Work in Progress.

Many factors contribute to poor adherence to medications. Some involve the patient, others the health care provider, while others concern limitations with the medications themselves.

Preparing for success: redesigning the diabetes office practice.

Improving health outcomes of patients with T2DM whose management includes injectable glucose-lowering therapy may require a redesign of the diabetes office practice to support patients' medical and psychosocial needs. This redesign may include the development of a participatory office practice wherein care is provided by a multidisciplinary diabetes care team. To make stepwise improvements in any facet of patient care, the PDSA cycle can be integrated into routine clinical practice.